Relationship of tranexamic acid therapy duration the hidden blood loss in ORIF treatment of complex tibial plateau fracture

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000032102

Enrollment

Unknown

Registered

2020-04-20

Start date

2020-04-19

Completion date

Unknown

Last updated

2020-04-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Complex tibial plateau fracture

Interventions

tranexamic acid IV group:IV use of tranexamic acid pre-operation and before closing incision

tranexamic acid topical group:topical use of tranexamic acid before closing incision

control group:use normal saline pre-operation or before closing incision

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Aged 18 years and above; Patients with complicated tibial plateau fracture admitted to hospital within 3 days after injury.

Exclusion criteria

Exclusion criteria: 1. Injured patients admitted for more than 3 days; 2. Hospital stay less than 48 hours; 3. Clinically active bleeding; 4. Known coagulation abnormalities (such as hemophilia); 5. Patients requiring continuous anticoagulant therapy (eg, mechanical valve patients); 6. Severe liver and kidney disease; 7. There is mental illness, etc., and patients with poor compliance are expected; 8. There are contraindications to the use of anticoagulant drugs.

Design outcomes

Primary

Measure	Time frame
volume of hidden blood lose;	—

Secondary

Measure	Time frame
Total blood loss;	—

Countries

China

Contacts

Public ContactKun Zhang

Xi'an Honghui Hospital

hhyyzk@126.com+86 15029219698

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026